Calico Life Sciences has entered an exclusive licensing agreement with Mabwell Bioscience for 9MW3811, a monoclonal antibody targeting interleukin-11. By inhibiting IL-11 and its downstream signaling pathways, the therapy suppresses inflammation and fibrotic processes. This collaboration focuses on developing treatments for idiopathic pulmonary fibrosis and related age-associated disorders.
Key points
- Calico licenses 9MW3811, an anti-IL-11 monoclonal antibody, from Mabwell Bioscience for up to $596M.
- 9MW3811 inhibits IL-11 signaling pathways to reduce inflammatory cascades and collagen deposition in fibrotic tissues.
- Phase I studies in China and Australia support US IND clearance, paving way for clinical trials in pulmonary fibrosis and age-related disorders.
Why it matters: Targeting IL-11 offers a novel anti-inflammatory and anti-fibrotic strategy that could shift current longevity therapeutic paradigms.
Q&A
- What is interleukin-11?
- How does a monoclonal antibody work?
- Why focus on fibrosis in aging?